BWAY

BrainsWay Ltd. (NASDAQ)

Healthcare — Medical Devices

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious and late-life depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.

Strong Buy 1.0 / 5 2 analysts

$15.29

$-0.22 (-1.42%)

Target: $17.50 (14.5%)

Price History

SMA 20 SMA 40 EMA 12 EMA 26 Bollinger

52-Week Range

Fundamentals

Market Cap	$613.58M
P/E Ratio (TTM)	69.50
Forward P/E	28.31
EPS (TTM)	$0.22
Dividend Yield	-
Profit Margin	15.58%
Revenue Growth	34.60%
ROE	12.55%
Debt/Equity	8.85
Recommendation	Strong Buy 1.0
Analyst Target	$17.50
Analysts	2
Indexes	NASDAQ

Technical Indicators

RSI (14)	64.8
Beta	0.15
SMA 20	-
SMA 40	-
52-Week High	$17.35
52-Week Low	$5.68
50-Day Avg	$15.37
200-Day Avg	$11.59
Avg Volume	132.4K
Volume	57.7K

Performance Analysis

BULLISH

BWAY shows predominantly bullish signals based on its fundamentals and technicals.

+ Showing strength at 82% of its 52-week range.

+ RSI at 64.8 shows positive momentum.

~ Price dropped below the 50-day average but remains above the 200-day — possible short-term weakness.

- P/E of 69.5 is elevated — the market expects high growth or it may be overvalued.

+ Strong revenue growth of 34.6% year-over-year.

+ Wall Street consensus is "Strong Buy" from 2 analysts.

+ Average analyst target of $17.50 implies 14.5% upside.

Recent News

Loading news...

Last updated: Jul 02, 2026 13:01 UTC

Back to Screener Export Report